



LAHIVE
&
COCKFIELD
L L P

PATENT & TRADEMARK OFFICE
COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICA NAND
MICHAEL PHILLIPS *
LISA M. DIROCCO
HATHAWAY P. RUSSELL ***
SENIOR COUNSEL
JAMES E. COCKFIELD
OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
MARIA LACCOTRIPE ZACHARAKIS, Ph.D. **
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. MCPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
PETER A. DIMATTIA
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

* Admitted in NY only
** Passed the Patent Bar Examination
*** Admitted in TX only

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/534,717

Title: *HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING*

Inventors: Jochen Salfeld *et al.*

Filed: March 24, 2000

Our Ref. No.: BBI-093CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

2/13/02

Date

Elizabeth A. Hanley, Esq Reg. No. 33,505

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

EH
Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

O I P E
FEB 27 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 05 2002
TECH CENTER 1600/2900

In re the application of: Jochen Salfeld *et al.*

Serial No.: 09/534,717

Filed: March 24, 2000

For: *HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING*

Docket No.: BBI-093CP

Group Art Unit: 1646

Examiner: Prasad, S.

#11
M.QJ
3/8/02

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date set forth below.

2/13/02

Date of Signature and of Mail Deposit

By:

Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Elizabeth A. Harley, Esq
Registration No. 33,505
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 2/13/02

GAD/EAH/PWD/ipc
Enclosures

APPLICANT FACSIMILE OF FORM PTO-144B REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO BBI-093CP	SERIAL NO. 09/534,717
P LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jochen Salfeld et al.		FILING DATE March 24, 2000	GROUP 1646

O
FEB 27 2002

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIATE
A1	4,816,397	3/89	Boss et al.	435	68	000/200
A2	5,658,754	8/97	Kawasaki	435	69.1	
A3	5,643,768	7/97	Kawasaki	435	91.21	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
A4	WO 9404679 A1	3/94	PCT			
A5	EP 0 659 766 A1	6/95	EPO			
A6	WO 9524918 A1	9/95	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A7	Balashov KE, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):599-603
A8	Barbas CF 3rd, et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978-82
A9	Berrebi D, et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol. 1998 Mar;152(3):667-72
A10	Bird RE, et al. Single-chain antigen-binding proteins. Science. 1988 Oct 21;242(4877):423-6
A11	Brown PS Jr, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2663-7
A12	Bucht A, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol. 1996 Mar;103(3):357-67
A13	Carter RW, et al. "Production and characterization of monoclonal antibodies to human interleukin-12," Hybridoma. 1997 Aug;16(4):363-9
A14	Clackson T, et al. Making antibody fragments using phage display libraries. Nature. 1991 Aug 15;352(6336):624-8
A15	Dall'Acqua W, et al. Antibody engineering. Curr Opin Struct Biol. 1998 Aug;8(4):443-50

Examiner	Date Considered
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449
REV 7-80U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

BBI-093CP

SERIAL NO.

09/534,717

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646



OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)		
B1		Fais S, et al. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res. 1994 Oct;14(5):235-8
B2		Fuchs P, et al. Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. Biotechnology (N Y). 1991 Dec;9(12):1369-72
B3		Fuss IJ, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996 Aug 1;157(3):1261-70
B4		Gately MK, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521
B5		Garrard LJ, et al. F _{ab} assembly and enrichment in a monovalent phage display system. Biotechnology (N Y). 1991 Dec;9(12):1373-7
B6		Gram H, et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3576-80
B7		Griffiths AD, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb;12(2):725-34
B8		Hanes J, et al. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A. 1997 May 13;94(10):4937-42
B9		Hawkins RE, et al. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992 Aug 5;226(3):889-96
B10		Hay BN, et al. Bacteriophage cloning and Escherichia coli expression of a human IgM Fab. Hum Antibodies Hybridomas. 1992 Apr;3(2):81-5
B11		Duchmann et al., Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996, 26:934-8 (Abstract)
B12		Hoogenboom HR, et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 1991 Aug 11;19(15):4133-7
B13		He M, et al. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 1997 Dec 15;25(24):5132-4
B14		Huse WD, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989 Dec 8;246(4935):1275-81

Examiner

Date Considered

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 05 2002
TECH CENTER 1600/2000

BBI-093CP

SERIAL NO.

09/534,717

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646

RECEIVED
TECH CENTER 1690
MAR 05 2002O I P E
FEB 27 2002

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

C1	Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5879-83
C2	Irving RA, et al. Affinity maturation of recombinant antibodies using E. coli mutator cells, Immunotechnology. 1996 Jun;2(2):127-43
C3	Junghans RP, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990 Mar 1;50(5):1495-502
C4	Kabat EA, et al. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. Ann N Y Acad Sci. 1971 Dec 31;190:382-93
C5	Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989 Sep 1;170(3):827-45
C6	Ling P, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995 Jan 1;154(1):116-27
C7	McCafferty J, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990 Dec 6;348(6301):552-4
C8	Monteleone G, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997 Apr;112(4):1169-78
C9	Morita Y, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998 Feb;41(2):306-14
C10	Neurath MF, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995 Nov 1;182(5):1281-90
C11	Parronchi P, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997 Mar;150(3):823-32
C12	Pini A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998 Aug 21;273(34):21769-76
C13	Pini A, et al. "Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma," J Immunol Methods. 1997 Aug 7;206(1-2):171-82
C14	Podlaski FJ, et al. Molecular characterization of interleukin 12. Arch Biochem Biophys. 1992 Apr;294(1):230-7

Examiner

Date Considered

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY DOCKET NO

BBI-093CP

SERIAL NO.

09/534,717

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Jochen Salfeld et al.

FILING DATE

March 24, 2000

GROUP

1646

RECEIVED
MAY 05 2000
TECH-GENIE/SP/2000

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		Seder RA, et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188-92
	D2	Sharon J. Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4814-7
	D3	Taylor LD, et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 1992 Dec 11;20(23):6287-95
	D4	Turka LA, et al. Interleukin 12: a potential link between nerve cells and the immune response in inflammatory disorders. Mol Med. 1995 Sep;1(6):690-9
	D5	Windhagen A, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995 Dec 1;182(6):1985-96
	D6	Winter G, et al. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433-55
	D7	Hamid Q, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996 Jul;98(1):225-31
	D8	Kabat, E.A., et al. <i>Sequences of Proteins of Immunological Interest, Fifth Edition</i> , U.S. Department of Health and Human Services, NIH Publication No. 91-3242, 1991 (Abstract) NTIS [online]. Retrieved from: Dialog Information Services, Palo Alto, CA, USA. NTIS Accession No. PB 91-192898, Dialog Accession NO. 1606873.

Examiner

Date Considered

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO BBI-093CP	SERIAL NO. 09/534,717
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jochen Salfeld et al.	FILING DATE March 24, 2000	GROUP 1646

FEB 27 2002

U.S. PATENT DOCUMENTS

EXAMINER'S ATTENT DOCUMENTS						
EXAMINER INITIAL <i>TRADEMARK</i>	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

SEARCHED PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
E1	WO 97/15327	5/97					
E2	WO 92/20791	11/92					
E3	WO 92/01047	1/92					
E4	WO 92/09690	7/92					

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Reference (including Author, Title, Date, Pertinent Pages, Etc.)		
E5	Kettleborough et al., Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991, 4:773-83 (Abstract)	
Examiner	Date Considered	
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	